IgH and Ig rearrangement analysis at diagnosis and relapses. Genomic DNA from diagnosis and relapses was subjected to PCR analysis using the FR1c-5Ј and JHc-3Ј IgH-specific primers and using the IRSS-5Ј and Kde-3Ј Ig-specific primers. Both IgH and Igspecific PCR products were spotted in duplicate on to the nylon membrane and hybridized with the patient-specific probe. Mononuclear cells (MNC) from a healthy volunteer donor served as a control. Dotblot results for IgH and Ig are shown in a and b, respectively. because the same IgH chain rearrangement was already present at the onset, while chain gene deletion was detectable at relapse only.
apparent that survivors of childhood cancer are at increased risk of second malignancies. [1] [2] [3] [4] [5] [6] A number of factors have been implicated in the etiology of second malignancies. The original cancer and associated genetic factors, immunosuppression, radiation therapy, and chemotherapy have been proposed as potential etiologic factors. [1] [2] [3] [4] [5] [6] In some instances an interaction of two or more of these factors has been associated with the development of second cancers. [3] [4] [5] For example, patients with Hodgkin's disease show an increased incidence of several malignancies following combined chemotherapy and radiation therapy, and patients with hereditary retinoblastoma are prone to developing osteogenic sarcoma when treated with radiation therapy. 4 The increased risk of secondary hematological malignancies in patients exposed to alkylating agents 7 and epipodophyllotoxins 2,3 is associated with the chromosomal rearrangements produced as a result of treatment with DNA damaging agents. The therapy-related acute myeloid leukemias (t-AMLs) associated with the antecedent use of topoisomerase-II (topo-II) poisons often display balanced chromosomal translocation involving the MLL gene at chromosome band 11q23. [1] [2] [3] Although less common than t-AML there are reports of therapy-related acute lymphoblastic leukemia (t-ALL) with 11q23 translocation. 8 However to our knowledge, no therapy-related non-Hodgkin's lymphomas (NHLs) with rearrangement of the 11q23 band have been reported. We report here a patient with therapy-related lymphoblastic lymphoma with an 11q23 translocation involving the MLL gene, following treatment of a primary hepatocellular carcinoma with cytotoxic chemotherapy.
The patient presented at 10 years of age with fever, anorexia, vomiting, abdominal pain and weight loss. He had massive splenomegaly and elevated serum levels of alpha-fetoprotein. The only significant family history was a paternal grandfather who had died of liver cancer. It was unclear whether this was primary or metastatic. There was no history of any other malignancies in the family. An abdominal CT scan revealed multiple enhancing low density lesions in the liver with lymphadenopathy in the retroperitoneum and porta-hepatis. Staging studies did not reveal any other evidence of disease. Bone marrow examination revealed only normal marrow elements without evidence of infiltrative disease. A biopsy from a mass lesion in the right lobe of the liver established the diagnosis of primary hepatocellular carcinoma. He was treated with cisplatinum and doxorubicin (total cumulative dose of doxorubicin was 380 mg/m 2 ). Following this treatment he had a partial response with complete resolution of splenomegaly and decrease in the size of the liver lesions. However the alpha-fetoprotein levels remained persistently elevated and the chemotherapy regimen was changed to etoposide, carboplatin and ifosfamide. He received only one course of this therapy. Re-evaluation demonstrated a solitary residual hepatic mass. He underwent a right hepatic lobectomy and cholecystectomy.
He was followed clinically and radiographically and was in remission for over 4 years when he developed fever, anorexia and weight loss. A CT scan of the abdomen revealed a new pelvic mass in the retrovesical region. He had no evidence of lymphadenopathy. A biopsy of the pelvic mass was reported as lymphoblastic lymphoma. The immunophenotype of the lymphoma cells was CD4 − consistent with the diagnosis of lymphoblastic lymphoma. Cytogenetic analysis revealed a t(1;13)(q4;q13) and t(11;19)(q23;p13) in 16 out of 20 cells. In addition, four of 20 cells had extra copies of chromosomes X, 5, 8, 13 and 14. Examination of bone marrow and cerebrospinal fluid did not display any evidence of malignant disease. The patient was treated with multiagent chemotherapy and radiotherapy. He initially showed a partial response, but developed bone marrow involvement and circulating lymphoblasts 8 months from the time of diagnosis of lymphoma. The malignant cells from his bone marrow during this phase of the disease had the same immunophenotype as the original lymphoma. He was treated with palliative radiation and died of progressive disease 12 months after the diagnosis of lymphoblastic lymphoma.
Genomic DNA extracted from the lymphoma cells was digested with BamHI, SstI, EcoRI, EcoRV and BglII. Figure 1 shows a Southern blot of these samples hybridized to the 0.7 kb MLL cDNA probe which encompasses MLL exons 5 to 7 and 9 to 11. One or more germline bands are seen depending on the restriction enzyme used. Two rearranged bands are seen in the tumor DNA in the BamHI and EcoRI digests, one rearranged band each in the SstI, EcoRI and EcoRV digests. The identification of rearranged bands in more than one digest using the 0.7 kb MLL probe confirms rearrangement of the MLL gene. Peripheral blood lymphoblasts harvested during the leukemic phase of the patient's disease showed an identical pattern of MLL gene rearrangements (data not shown). Figure 2 shows a Southern blot containing BamHI digested DNA extracted from peripheral blood lymphocytes obtained prior to the leukemic phase of his disease hybridized to the 0.7 kb MLL probe. A single band representing the 8.3 kb genomic MLL fragment is seen indicating that the MLL rearrangement in this patient is not constitutional and is not due to a restriction fragment length polymorphism.
11q23 translocations disrupting the MLL gene have been frequently reported in t-AML following treatment with epipodophyllotoxins and have been associated with a poor prognosis. 2, 3 There are also reports of T-cell acute lymphoblastic leukemia (ALL) with the t(11;19) translo-
Figure 1
Southern blot showing MLL rearrangements. Genomic DNA was digested with the indicated restriction enzymes and hybridized to the 0.7B cDNA probe. Pt, genomic DNA extracted from the lymphoblastic lymphoma sample; C, control DNA extracted from the MOLT-4 cell line which is known to have a germline MLL locus. Size standards are as indicated. An 8.3 kb germline fragment is seen in the BamHI digest. One or more rearranged, non-germline fragments are seen with all digests. cation. 9 Although the morphology of the lymphoblasts in T cell leukemia and T cell lymphoblastic lymphoma are similar, and these entities are often thought to represent different presentations of the same disease, to our knowledge, there are no reports of therapy-related nonHodgkin's lymphoma with MLL gene rearrangement following cytotoxic chemotherapy. In fact, there are no reports of T cell lymphoblastic lymphoma either de novo or therapy-related with an MLL gene rearrangement. This report documents the fact that T cell lymphoblastic lymphoma with MLL rearrangement can occur as a therapy-related malignancy. The rearrangement of the MLL gene was also seen in the lymphoblasts from the peripheral blood during the leukemic phase of the disease.
Most of the therapy-related lymphomas are lymphoproliferative or EBV-related 5, 6 and occur in organ transplant recipients receiving immunosuppressive therapy with cyclosporine, OKT3 or anti-thymocyte globulin. In these EBV-related lymphoproliferative diseases, it is thought that EBV-infected host lymphocytes undergo a polyclonal proliferation, in the absence of suppressor T-lymphocytes, which have been reduced in number due to the immunosuppressive therapy. With ongoing proliferation there is an increased risk of additional recombinational events which may result in the malignant phenotype.
Therapy-related leukemias are thought to arise as a direct consequence of chromosomal rearrangements caused by cytotoxic chemotherapy. 2, 3, 7 Therapy-related leukemias are most often t-AML, although therapy-related acute lymphoblastic leukemias (t-ALL), therapy-related acute leukemias of unspecified origin and therapy-related myelodysplastic syndromes have also been described. 2 In general, tAMLs can be placed into distinct categories based on clinical and biologic findings. t-AMLs following treatment with alkylating agents typically present 4-6 years after therapy (range 1-20 years) with a myelodysplastic syndrome which evolves into an acute leukemia. Cytogenetically, these t-AMLs are often associated with deletions of chromosomes 5 and 7. In contrast, t-AMLs associated with the use of topo-II poisons present abruptly, usually without an antecedent myelodysplastic phase, following a shorter latency period of 0.5-4.5 years and are often associated with balanced translocations of the MLL gene. 7 Lymphoblastic lymphoma occurred in the present patient 63 months after initiation of anthracycline therapy and 54 months after
Figure 2
The MLL rearrangement was not constitutional. BamHI digested DNA extracted from the patient's peripheral blood lymphocytes (PBL) prior to the leukemic phase was hybridized to the 0.7B MLL probe. The MOLT 4 cell line is used as a germline control. Size standards are as indicated. A single germline fragment is seen in both the control and the patient PBL sample indicating that the MLL rearrangement seen in the tumor cells is not due to a restriction fragment length polymorphism. treatment with an alkylating agent and an epipodophyllotoxin. While it is possible that therapy-related lymphoblastic lymphoma has a longer latency period than therapy-related leukemia, wide variations in latency periods for secondary malignancies with the 11q23 translocation following similar treatment regimens have been reported. 2 What is the cause for the second malignancy in this patient? There was no history of a hereditary predisposition to malignancies in the family. To our knowledge there is no association between primary hepatocellular carcinoma and lymphoblastic lymphoma and the possibility that these were two unrelated de novo malignancies cannot be eliminated. However, the known association between 11q23 translocations and therapy-related acute leukemias make it likely that the lymphoblastic lymphoma in this patient was a direct result of an MLL translocation induced by treatment with DNA damaging agents. The mechanisms(s) of illegitimate recombination leading to MLL rearrangements is not well understood nor is the role of topo-II in this process. These topics have recently been reviewed. 3 We conclude that therapy-related lymphoblastic lymphoma can be associated with 11q23 translocations involving the MLL gene. While the case described here had a slightly longer latency period compared with the t-AMLs associated with the topo II poisons, it seems likely Extensive bone marrow necrosis associated with multiple myeloma TO that the mechanism of 11q23 translocation in this patient is similar to that seen in t-AMLs associated with topo II poisons. Although this entity is presumably rare, the true frequency with which therapyrelated lymphoblastic lymphoma occurs following aggressive, multiagent chemotherapy can only be ascertained by careful follow-up of cancer survivors.
extensive BMN is characterized by the development of fever, bone pain, a leukoerythroblastic peripheral blood film, variable degrees of pancytopenia and elevations of lactate dehydrogenase and alkaline phosphatase. BMN has been reported in patients with different malignancies, sickle cell disease, disseminated intravascular coagulation (DIC), antiphospholipid syndrome (APS), as well as infections. 1 There are case reports linking certain medications including fludarabine, interferon alfa to the development of BMN as well. 2, 3 Here we report two cases of multiple myeloma (MM) with extensive BMN.
In case 1, a 45-year-old man was diagnosed with Durie-Salmon stage III MM in June 1995. A serum immunoelectrophoresis and
